Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02).
Feng-Hua WangXiao-Li WeiJifeng FengQi LiNong XuXi-Chun HuWangjun LiaoYi JiangXiao-Yan LinQing-Yuan ZhangXiang-Lin YuanHai-Xin HuangYe ChenGuang-Hai DaiJian-Hua ShiLin ShenShu-Jun YangYong-Qian ShuYun-Peng LiuWeifeng WangHai WuHui FengSheng YaoRui-Hua XuPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The POLARIS-02 study demonstrated a manageable safety profile and durable clinical response of toripalimab in patients with chemorefractory metastatic NPC. An early decrease in plasma EBV DNA copy number correlated with favorable response.
Keyphrases
- phase ii
- clinical trial
- copy number
- mitochondrial dna
- open label
- squamous cell carcinoma
- small cell lung cancer
- genome wide
- epstein barr virus
- randomized controlled trial
- diffuse large b cell lymphoma
- circulating tumor
- single molecule
- study protocol
- cell free
- placebo controlled
- metastatic colorectal cancer
- newly diagnosed
- circulating tumor cells